rv568
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01230645)
Timeline
Indications
Mechanism of action
- MAP kinase p38 betaINHIBITOR
MAPK11 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rv568
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01661244 | Phase 1 | Sep 1, 2012 | RespiVert |
| NCT01475292 | Phase 2 | Nov 1, 2011 | IQVIA, RespiVert |
| NCT01230619 | Phase 2 | Oct 1, 2010 | Medical University of Vienna, RespiVert |
| NCT01230645 | Phase 1 | Oct 1, 2010 | hVIVO Services Limited, RespiVert |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RespiVert | For profit | 4 | 4 | 2 | 2010 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2010 |
| IQVIA | For profit | 1 | 0 | 1 | 2011 |
| Medical University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1